Combination of matrine and sorafenib decreases the aggressive phenotypes of hepatocellular carcinoma cells

Chemotherapy

Volumn 60, Issue 2, 2014, Pages 112-118

  Lin, Yan ^a   Lin, Lianjie ^a   Jin, Yu ^a   Zhang, Ying ^a   Wang, Dongxu ^a   Tan, Yue ^a   Zheng, Changqing ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Combination therapy; Growth suppression; Matrine; microRNA

Indexed keywords

MATRINE; MICRORNA 21; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SORAFENIB; ALKALOID; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; QUINOLIZINE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; HEPG2 CELL LINE; LIVER NEOPLASMS; PATHOLOGY; PHENOTYPE; PHYSIOLOGY;

ALKALOIDS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENOTYPE; PHENYLUREA COMPOUNDS; QUINOLIZINES;

EID: 84925390465     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000371736     Document Type: Article

References (33)

1. Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group: Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 2012; 23(suppl 7):vii41-vii48
2. Wang X, Zhang A, Sun H: Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 2013; 57: 2072-2077
3. Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H: Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. Chemotherapy 2012; 58: 468-474
4. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
6. Abdel-Rahman O, Fouad M: Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol 2014; 91: 1-8
7. Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q, Su C: Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol 2014; 35: 5111-5119
8. Jin H, Sun Y, Wang S, Cheng X: Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells. Int J Mol Sci 2013; 14: 16040-16057
9. Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, Wu J, Yu K, Han Y: Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One 2012; 7:e46853
10. Vermeulen K, Van Bockstaele DR, Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627-639
11. Fauser JK, Matthews GM, Cummins AG, Howarth GS: Induction of apoptosis by the medium-chain length fatty acid lauric acid in colon cancer cells due to induction of oxidative stress. Chemotherapy 2013; 59: 214-224
12. Qin XG, Hua Z, Shuang W, Wang YH, Cui YD: Effects of matrine on HepG2 cell proliferation and expression of tumor relevant proteins in vitro. Pharm Biol 2010; 48: 275-281
13. Zhang JQ, Li YM, Liu T, He WT, Chen YT, Chen XH, Li X, Zhou WC, Yi JF, Ren ZJ: Antitumor effect of matrine in human hepatoma G2 cells by inducing apoptosis and autophagy. World J Gastroenterol 2010; 16: 4281-4290
14. Hu MJ, Zeng H, Wu YL, Zhang YP, Zhang S, Qiao MM, Fu H: Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice. Chin J Dig Dis 2005; 6: 68-71
15. Li LQ, Li XL, Wang L, Du WJ, Guo R, Liang HH, Liu X, Liang DS, Lu YJ, Shan HL, Jiang HC: Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells. Cell Physiol Biochem 2012; 30: 631-641
16. van Rooij E: The art of microRNA research. Circ Res 2011; 108: 219-234
17. Li Z, Rana TM: Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014; 13: 622-638
18. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-658
19. Wei G1, Wang M, Hyslop T, Wang Z, Carr BI: Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. Int J Cancer 2010; 127: 2949-2958
20. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-Ct method. Methods 2001; 25: 402-408
21. Naqi N, Ahmad S, Murad S, Khattak J: Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label phase II feasibility study. Hematol Oncol Stem Cell Ther 2014; 7: 27-31
22. Hagihara A, Ikeda M, Ueno H, Morizane C, Kondo S, Nakachi K, Mitsunaga S, Shimizu S, Kojima Y, Suzuki E, Katayama K, Imanaka K, Tamai C, Inaba Y, Sato Y, Kato M, Okusaka T: Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma. Cancer Sci 2014; 105: 354-358
23. Finn RS, Poon RT, Yau T, Klumpen HJ, Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J: Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013; 59: 1271-1277
24. Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W: Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling. Br J Cancer 2013; 109: 342-350
25. Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS: A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. Am J Surg 2012; 204: 895-900
26. Dai ZJ, Gao J, Ji ZZ, Wang XJ, Ren HT, Liu XX, Wu WY, Kang HF, Guan HT: Matrine induces apoptosis in gastric carcinoma cells via alteration of Fas/FasL and activation of caspase-3. J Ethnopharmacol 2009; 123: 91-96
27. Xie F1, Su M, Qiu W, Zhang M, Guo Z, Su B, Liu J, Li X, Zhou L: Kaempferol promotes apoptosis in human bladder cancer cells by inducing the tumor suppressor, PTEN. Int J Mol Sci 2013; 14: 21215-21226
28. Li D, Zhang Y, Xie Y, Xiang J, Zhu Y, Yang J: Enhanced tumor suppression by adenoviral PTEN gene therapy combined with cisplatin chemotherapy in small-cell lung cancer. Cancer Gene Ther 2013; 20: 251-259
29. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027
30. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, Tatsumi T, Ishida H, Noda T, Nagano H, Doki Y, Mori M, Hayashi N: The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenibinduced apoptosis in human hepatocellular carcinoma. J Hepatol 2010; 52: 698-704
31. Mao K, Zhang J, He C, Xu K, Liu J, Sun J, Wu G, Tan C, Zeng Y, Wang J, Xiao Z: Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Cancer Lett 2014; 352: 245-252
32. Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S, De Petro G: Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer 2013; 12: 162
33. Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M: MicroRNA-21 induces resistance to the anti-tumour effect of interferon-/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010; 103: 1617-1626.